syndicate of existing Ikena investors

Ikena Oncology is a clinical-stage biotechnology company focused on developing precision oncology therapies for cancer patients with specific genetic alterations. The company's lead programs have included IK-930, a TEAD inhibitor targeting the Hippo pathway, and IK-595, a MEK-RAF complex inhibitor. In May 2024, Ikena announced a significant strategic shift, discontinuing clinical development of its lead assets to preserve capital and exploring strategic alternatives such as a merger or sale. The company is currently focused on maximizing shareholder value through this strategic review process while maintaining its biomarker-driven approach to drug discovery.